Digoxin: Difference between revisions
(moved Digoxin to Digoxin Toxicity) |
(Switch SMW query from broadtable to table format for better layout with TOC) |
||
| (27 intermediate revisions by 11 users not shown) | |||
| Line 1: | Line 1: | ||
# | ==General== | ||
*Type: Cardiac glycoside; [[CHF medications]] | |||
*Mechanism of action- Inhibits Na+/K+ ATPase, leading to an increase in intracellular sodium that can increase cardiac contractility | |||
*Dosage Forms: PO, IV, IM | |||
*Common Trade Names: Digitek, Digox, Lanoxin | |||
==Adult Dosing== | |||
*Loading dose = 0.25mg IV q2hr until effect (max total = 1.5mg) | |||
*in acute [[atrial fibrillation with RVR]] with heart failure = 0.5mg IV, then 0.25mg IV q4hr until effect or max 1.5mg | |||
==Pediatric Dosing== | |||
==Special Populations== | |||
*[[Drug Ratings in Pregnancy|Pregnancy Rating]]: C | |||
*[[Lactation risk categories|Lactation risk]]: | |||
*Renal Dosing | |||
**Adult | |||
**Pediatric | |||
*Hepatic Dosing | |||
**Adult | |||
**Pediatric | |||
==Indications== | |||
*RVR control in a-fib/flutter, PSVT | |||
==Contraindications== | |||
*Allergy to class/drug | |||
*[[WPW]] | |||
**Increases conduction velocity in atrial tissue | |||
==Adverse Reactions== | |||
''[[Digoxin toxicity]]'' | |||
*GI: nausea and vomiting, diarrhea, abdominal pain | |||
*CV: Bradycardia, SA/AV block, ventr arrhythmias | |||
*Neuro: [[altered mental status]], visual disturbances (yellow-tinted vision) | |||
==Pharmacology== | |||
*Onset of action | |||
**IV = 5-30 minutes | |||
**PO = 0.5-2 hours | |||
*Half-life: 36-48 hours (may be increased with renal impairment) | |||
*Absorption: 60-80% absorption after oral administration | |||
*Metabolism: ~16% is converted to metabolites | |||
*Excretion: Almost entirely by the kidneys | |||
==Mechanism of Action== | |||
{{Digoxin mechanism}} | |||
==Comments== | |||
==Indications by Condition== | |||
''The following table is automatically generated from disease/condition pages across WikEM.'' | |||
{{#ask:[[Has DrugName::Digoxin]] | |||
|?Has Indication=Indication | |||
|?Has Dose=Dose | |||
|?Has Context=Context | |||
|?Has Route=Route | |||
|?Has Population=Population | |||
|format=table | |||
|headers=plain | |||
|mainlabel=- | |||
|sort=Has Indication | |||
|limit=50 | |||
}} | |||
==See Also== | |||
*[[Digoxin Toxicity]] | |||
*[[Antiarrhythmics]] | |||
==References== | |||
<references/> | |||
[[Category:Pharmacology]] | |||
[[Category:Cardiology]] | |||
Latest revision as of 21:56, 20 March 2026
General
- Type: Cardiac glycoside; CHF medications
- Mechanism of action- Inhibits Na+/K+ ATPase, leading to an increase in intracellular sodium that can increase cardiac contractility
- Dosage Forms: PO, IV, IM
- Common Trade Names: Digitek, Digox, Lanoxin
Adult Dosing
- Loading dose = 0.25mg IV q2hr until effect (max total = 1.5mg)
- in acute atrial fibrillation with RVR with heart failure = 0.5mg IV, then 0.25mg IV q4hr until effect or max 1.5mg
Pediatric Dosing
Special Populations
- Pregnancy Rating: C
- Lactation risk:
- Renal Dosing
- Adult
- Pediatric
- Hepatic Dosing
- Adult
- Pediatric
Indications
- RVR control in a-fib/flutter, PSVT
Contraindications
- Allergy to class/drug
- WPW
- Increases conduction velocity in atrial tissue
Adverse Reactions
- GI: nausea and vomiting, diarrhea, abdominal pain
- CV: Bradycardia, SA/AV block, ventr arrhythmias
- Neuro: altered mental status, visual disturbances (yellow-tinted vision)
Pharmacology
- Onset of action
- IV = 5-30 minutes
- PO = 0.5-2 hours
- Half-life: 36-48 hours (may be increased with renal impairment)
- Absorption: 60-80% absorption after oral administration
- Metabolism: ~16% is converted to metabolites
- Excretion: Almost entirely by the kidneys
Mechanism of Action
- Inhibits Na+/K+ ATPase in the myocardium[1]
- Causes increase in intracellular sodium levels
- Results in reversal of sodium-calcium exchanger
- Normally imports three extracellular sodium ions into the cardiac myocyte in exchange for one intracellular calcium being exported
- Sodium accumulates intracellularly and is exchanged for Calcium.
- Causes an increase in the intracellular calcium concentration increasing contractility
- Also a lengthening of phase 4 and phase 0 of the cardiac action potential which ultimately decreases heart rate
- Summary
- Inhibits NaK pump
- Positive inotropy
- Negative chronotropy/dromotropy
- Indirect vagal stimulator
- Inhibits NaK pump
Comments
Indications by Condition
The following table is automatically generated from disease/condition pages across WikEM.
| Indication | Dose | Context | Route | Population |
|---|---|---|---|---|
| Atrial fibrillation (main) | 500 mcg IV, then 250 mcg q4h x2 (total 1000 mcg digitizing dose) | Rate control (if hypotensive or advanced HF) | IV | Adult |
See Also
References
- ↑ Gheorghiade M. et al. Digoxin in the Management of Cardiovascular Disorders. Circulation. 2004; 109: 2959-2964
